Insulin (Oral Inhalation) and Pentam

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using pentamidine together with insulin inhalation, rapid acting can alter the effects of insulin inhalation, rapid acting. Pentamidine may interfere with blood glucose control. Consistent timing of dosing of other medications relative to inhaled human insulin administration is recommended. You should be counseled to recognize symptoms of hypoglycemia (low blood sugar) such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations. If hypo- or hyperglycemia (high blood sugar) occurs during pentamidine therapy, you should contact your doctor immediately. Blood glucose should be monitored closely, and the insulin dose adjusted accordingly. You may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: It is unknown whether inhaled pentamidine can affect the absorption of inhaled human insulin. Consistent timing of dosing of other inhaled products relative to inhaled human insulin administration is recommended.

MONITOR: Pentamidine may interfere with the therapeutic effects of insulin and oral antidiabetic agents. The use of pentamidine has been associated with disturbances in blood glucose homeostasis due to direct toxic effects on beta cells of the pancreas. Hypoglycemia, which may be severe and/or prolonged, as well as hyperglycemia and insulin-dependent diabetes mellitus, the latter of which may be irreversible, have been reported. The onset of pentamidine-induced hypoglycemia generally varied from 5 to 7 days after start of therapy to several days after therapy stops. In some cases, hyperglycemia and progression to diabetes followed, although these effects have occurred independently also. Pancreatic toxicity has been reported with both parenteral use and, less frequently, oral inhalation of pentamidine. The risk appears to be related to total cumulative dosage and prior therapy with the drug, particularly within the last 3 months. Renal impairment also appears to be a risk factor.

MANAGEMENT: Blood glucose should be monitored closely during and after pentamidine therapy in patients receiving insulin and/or oral antidiabetic agents, especially if they are elderly or have renal impairment. Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations. If hypo- or hyperglycemia occurs during pentamidine therapy, patients should initiate appropriate remedial therapy immediately, discontinue pentamidine therapy, and contact their physician.

Insulin (Oral Inhalation)

Generic Name: insulin inhalation, rapid acting

Brand name: Afrezza, Exubera, EXUBERA Combination Pack 12, EXUBERA Combination Pack 15, EXUBERA Kit, Afrezza 4 unit- 8 unit, Afrezza 8 unit- 12 unit, Afrezza Titration Pack, Exubera

Synonyms: Insulin (inhalation)

What is Insulin (Oral Inhalation)?

Pentam

Generic Name: pentamidine

Brand name: Pentam, Nebupent, Pentam 300

Synonyms: n.a.

What is Pentam?